(Q46836740)

25 December 2017

title

Early clinical experience with anidulafungin at a large tertiary care medical center (English)

1 reference

25 December 2017

author name string

Benjamin D Brielmaier

1

1 reference

25 December 2017

Ed Casabar

2

1 reference

25 December 2017

Christine M Kurtzeborn

3

1 reference

25 December 2017

Peggy S McKinnon

4

1 reference

25 December 2017

David J Ritchie

5

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 January 2008

1 reference

25 December 2017

published in

Pharmacotherapy

1 reference

25 December 2017

volume

28

1 reference

25 December 2017

issue

1

1 reference

25 December 2017

page(s)

64-73

1 reference

25 December 2017

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Aspergillosis case-fatality rate: systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

The impact of candidemia on length of hospital stay, outcome, and overall cost of illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Invasive mold infections in allogeneic bone marrow transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Invasive candidiasis in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Epidemiology of invasive candidiasis: a persistent public health problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

21 January 2018

Invasive candidiasis.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Micafungin: a new echinocandin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Anidulafungin: a novel echinocandin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Metronidazole and alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Effect of metronidazole on liver alcohol dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Efficacy and safety of caspofungin therapy in children with invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Anidulafungin versus fluconazole for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Caspofungin: first approved agent in a new class of antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Lack of disulfiram-like reaction with metronidazole and ethanol

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Do ethanol and metronidazole interact to produce a disulfiram-like reaction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Development of candidemia on caspofungin therapy: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.1.64

21 January 2018

Identifiers

DOI

10.1592/PHCO.28.1.64

1 reference

25 December 2017

1 reference

25 December 2017